Treats C. difficile -associated diarrhea. ANDA 219559, held by Apotex. Fidaxomicin.
As of Nov 16, 2026, ANDA 219559 (Fidaxomicin), held by Apotex, was first approved by FDA on Feb 2, 2026, with 0 approved supplements and 0 published complete response letters.
Fidaxomicin tablets are a macrolide antibacterial indicated in adult patients for the treatment of C. difficile -associated diarrhea. To reduce the development of drug-resistant bacteria and maintain the effectiveness of fidaxomicin tablets and other antibacterial drugs, fidaxomicin tablets should be used only to treat infections that are proven or strongly suspected to be caused by C. difficile. 1.1 Clostridioides difficile -Associated Diarrhea
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 2, 2026 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fidaxomicin200MG · tablet;oral | Fidaxomicin | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters